Cohance Lifesciences is deploying USD 18 million from internal accruals to reorganize its Antibody-drug Conjugate (ADC) business. The firm will increase its stake in NJ Bio to 67.3% for USD 13 million and acquire a 65% controlling stake in Aruka Bio for USD 5 million. This move aims to integrate service-based operations with proprietary drug development, creating an end-to-end platform. Both transactions are slated for completion by September 2026.
Cohance Lifesciences Reorganizes ADC Business with USD 18 Million Investment
Total Investment: USD 18 million; Stake Acquisition: 67.3% in NJ Bio and 65% in Aruka Bio.
Reader Takeaway: Cohance aims to unify its ADC manufacturing and discovery services to streamline operations and market reach.
What just happened
Cohance Lifesciences has announced a strategic reorganization of its Antibody-drug Conjugate (ADC) business units. The company is investing a total of USD 18 million, funded through internal accruals. This includes a USD 13 million investment to raise its stake in NJ Bio from 56% to 67.3% and a USD 5 million investment to acquire a 65% majority stake in Aruka Bio. Both deals are expected to be finalized by September 2026.
Why this matters
The reorganization creates a clearer division of labor between service-oriented operations and drug development. By deepening its ownership in NJ Bio, Cohance secures more control over customer-facing services that complement its existing manufacturing platform. Simultaneously, taking a majority stake in Aruka Bio allows the company to aggressively push a proprietary drug pipeline, moving toward an end-to-end service model.
Management Commentary
Dr. Naresh Jain will lead this transition, moving from his current role at NJ Bio to become the CEO of Aruka Bio. He will continue to support NJ Bio as a strategic advisor. Umang Vohra, Executive Chairman and Group CEO of Cohance, stated that this structural change is designed to improve business performance and ensure both units can focus on their respective growth targets.
Risks to watch
Investors should note that the completion of these acquisitions is subject to final definitive agreements and necessary regulatory approvals. While the funding is derived from internal liquidity, the integration of two distinct business models carries operational execution risks. The success of this move depends on the effective transition of leadership and the ability to maintain current service levels at NJ Bio while scaling the pre-clinical pipeline at Aruka Bio.
What to track next
Watch for the formal closure of the transactions by September 2026. Further updates on the progress of Aruka Bio’s drug development partnerships will also be key indicators of whether this capital allocation is generating the expected strategic value.